Immuno-Oncology | Specialty

Dr. Carbone on the Impact of Immunotherapy in Lung Cancer

May 19th 2020

David P. Carbone, MD, PhD, discusses the impact of immunotherapy on lung cancer.

Dr. Rugo on Recent Updates With Immunotherapy in TNBC

May 19th 2020

Hope S. Rugo, MD, discusses recent updates with immunotherapy in triple negative breast cancer.

Dr. Savvides on the Utility of Immunotherapy in Lung Cancer

May 19th 2020

Panayiotis S. Savvides, MD, discusses the utility of immunotherapy in lung cancer.

Dr. Carbone on the Impact of Immunotherapy in Lung Cancer

May 19th 2020

David P. Carbone, MD, PhD, discusses the impact of immunotherapy on lung cancer.

Dr. Rugo on Recent Updates With Immunotherapy in TNBC

May 19th 2020

Hope S. Rugo, MD, discusses recent updates with immunotherapy in triple negative breast cancer.

FDA Approves Nivolumab/Ipilimumab for Frontline Advanced PD-L1+ NSCLC

May 15th 2020

The FDA has approved the combination of nivolumab and ipilimumab for the first-line treatment of patients with PD-L1–positive metastatic or recurrent non–small cell lung cancer that does not have EGFR or ALK genomic tumor aberrations.

Rugo Relays the State of Immunotherapy in TNBC

May 14th 2020

Hope S. Rugo, MD, discusses the research that was born from the results of the IMpassion130 trial and the future of immunotherapy in triple-negative breast cancer.

Rugo Relays the State of Immunotherapy in TNBC

May 14th 2020

Hope S. Rugo, MD, discusses the research that was born from the results of the IMpassion130 trial and the future of immunotherapy in triple-negative breast cancer.

Study of Anti-CD73 Immunotherapy TJD5 in Solid Tumors Launches in China

May 13th 2020

The first patient has been dosed in a phase 1/2 trial of TJD5 in Chinese patients with advanced solid tumors, according to I-Mab, the company developing the CD73 antibody.

Novel Combo Elicits Clinical Responses in Patients With "Cold" Melanomas

May 13th 2020

Combining the PD-1 inhibitor pembrolizumab with intratumoral plasmid interkeukin-12 electroporation elicited clinical responses in patients with immunologically quiescent advanced melanoma.

Roswell Park's Dr. Pawel Kalinski to Lead $14.5M NCI-Funded Immunotherapy Effort

March 31st 2020

A team led by Pawel Kalinski, MD, PhD, of Roswell Park Comprehensive Cancer Center has earned a five-year, $14.54 million award from the National Cancer Institute to expand a promising immunotherapy platform.

RET Inhibition Research: Next Steps

March 30th 2020

The Future of RET Inhibition in Clinical Practice

March 30th 2020

RET Inhibitors in Development

March 30th 2020

Effect of NGS Wait Time on Decision Making

March 30th 2020

Targeted Therapy Benefit for Actionable Mutations

March 30th 2020

The Impact of Upfront NGS Testing on Overall Outcomes

March 30th 2020

The Importance of NGS Testing in NSCLC

March 30th 2020

Multikinase TKI Toxicity Profile

March 30th 2020

The Role of Multikinase TKIs for NSCLC

March 30th 2020